PortalPublikationenAngiotensin II-antagonist in paroxysmal atrial fibrillation ...

Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.

Standard

Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. / Goette, Andreas; Schön, Norbert; Kirchhof, Paulus; Breithardt, Günter; Fetsch, Thomas; Häusler, Karl Georg; Klein, Helmut U; Steinbeck, Gerhard; Wegscheider, Karl; Meinertz, Thomas.

in: CIRC-ARRHYTHMIA ELEC, Jahrgang 5, Nr. 1, 1, 2012, S. 43-51.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Goette, A, Schön, N, Kirchhof, P, Breithardt, G, Fetsch, T, Häusler, KG, Klein, HU, Steinbeck, G, Wegscheider, K & Meinertz, T 2012, 'Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.', CIRC-ARRHYTHMIA ELEC, Jg. 5, Nr. 1, 1, S. 43-51. <http://www.ncbi.nlm.nih.gov/pubmed/22157519?dopt=Citation>

APA

Goette, A., Schön, N., Kirchhof, P., Breithardt, G., Fetsch, T., Häusler, K. G., Klein, H. U., Steinbeck, G., Wegscheider, K., & Meinertz, T. (2012). Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. CIRC-ARRHYTHMIA ELEC, 5(1), 43-51. [1]. http://www.ncbi.nlm.nih.gov/pubmed/22157519?dopt=Citation

Vancouver

Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. CIRC-ARRHYTHMIA ELEC. 2012;5(1):43-51. 1.

Bibtex

@article{a567f39d342349e1a3b4b67b66e734a6,
title = "Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.",
abstract = "Unlike antiarrhythmic drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with structural heart disease is well established. The clinical efficacy of ARBs to prevent atrial fibrillation (AF) so far only has been shown in patients with structural heart disease. Here, we report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients with paroxysmal AF without structural heart disease.",
keywords = "Humans, Male, Female, Middle Aged, Prospective Studies, Treatment Outcome, Follow-Up Studies, Time Factors, Incidence, Double-Blind Method, Dose-Response Relationship, Drug, Germany/epidemiology, Angiotensin II Type 1 Receptor Blockers/*administration & dosage, Atrial Fibrillation/*drug therapy/epidemiology/physiopathology, Electrocardiography/drug effects, Imidazoles/*administration & dosage, Tachycardia, Paroxysmal/*drug therapy/epidemiology/physiopathology, Tetrazoles/*administration & dosage, Humans, Male, Female, Middle Aged, Prospective Studies, Treatment Outcome, Follow-Up Studies, Time Factors, Incidence, Double-Blind Method, Dose-Response Relationship, Drug, Germany/epidemiology, Angiotensin II Type 1 Receptor Blockers/*administration & dosage, Atrial Fibrillation/*drug therapy/epidemiology/physiopathology, Electrocardiography/drug effects, Imidazoles/*administration & dosage, Tachycardia, Paroxysmal/*drug therapy/epidemiology/physiopathology, Tetrazoles/*administration & dosage",
author = "Andreas Goette and Norbert Sch{\"o}n and Paulus Kirchhof and G{\"u}nter Breithardt and Thomas Fetsch and H{\"a}usler, {Karl Georg} and Klein, {Helmut U} and Gerhard Steinbeck and Karl Wegscheider and Thomas Meinertz",
year = "2012",
language = "English",
volume = "5",
pages = "43--51",
journal = "CIRC-ARRHYTHMIA ELEC",
issn = "1941-3149",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.

AU - Goette, Andreas

AU - Schön, Norbert

AU - Kirchhof, Paulus

AU - Breithardt, Günter

AU - Fetsch, Thomas

AU - Häusler, Karl Georg

AU - Klein, Helmut U

AU - Steinbeck, Gerhard

AU - Wegscheider, Karl

AU - Meinertz, Thomas

PY - 2012

Y1 - 2012

N2 - Unlike antiarrhythmic drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with structural heart disease is well established. The clinical efficacy of ARBs to prevent atrial fibrillation (AF) so far only has been shown in patients with structural heart disease. Here, we report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients with paroxysmal AF without structural heart disease.

AB - Unlike antiarrhythmic drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with structural heart disease is well established. The clinical efficacy of ARBs to prevent atrial fibrillation (AF) so far only has been shown in patients with structural heart disease. Here, we report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients with paroxysmal AF without structural heart disease.

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Prospective Studies

KW - Treatment Outcome

KW - Follow-Up Studies

KW - Time Factors

KW - Incidence

KW - Double-Blind Method

KW - Dose-Response Relationship, Drug

KW - Germany/epidemiology

KW - Angiotensin II Type 1 Receptor Blockers/administration & dosage

KW - Atrial Fibrillation/drug therapy/epidemiology/physiopathology

KW - Electrocardiography/drug effects

KW - Imidazoles/administration & dosage

KW - Tachycardia, Paroxysmal/drug therapy/epidemiology/physiopathology

KW - Tetrazoles/administration & dosage

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Prospective Studies

KW - Treatment Outcome

KW - Follow-Up Studies

KW - Time Factors

KW - Incidence

KW - Double-Blind Method

KW - Dose-Response Relationship, Drug

KW - Germany/epidemiology

KW - Angiotensin II Type 1 Receptor Blockers/administration & dosage

KW - Atrial Fibrillation/drug therapy/epidemiology/physiopathology

KW - Electrocardiography/drug effects

KW - Imidazoles/administration & dosage

KW - Tachycardia, Paroxysmal/drug therapy/epidemiology/physiopathology

KW - Tetrazoles/administration & dosage

M3 - SCORING: Journal article

VL - 5

SP - 43

EP - 51

JO - CIRC-ARRHYTHMIA ELEC

JF - CIRC-ARRHYTHMIA ELEC

SN - 1941-3149

IS - 1

M1 - 1

ER -